GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill for the nine month period ended September 30, 2013 and for the year ended December 31, 2012 are as follows:



	Clinical Diagnostics Laboratory Segment						Other Segment				Total
	September 30, 2013			December 31, 2012			September 30, 2013		December 31, 2012		September 30, 2013			December 31, 2012
Balance as of January 1	$	2,857.1		$	2,643.5		$	44.6	$	38.3	$	2,901.7		$	2,681.8
Goodwill acquired during the period	78.8			219.1			11.4		5.4		90.2			224.5
Adjustments to goodwill	(1.2		)	(5.5		)	0.2		0.9		(1.0		)	(4.6		)
Balance at end of period	$	2,934.7		$	2,857.1		$	56.2	$	44.6	$	2,990.9		$	2,901.7

The components of identifiable intangible assets are as follows:



	September 30, 2013							December 31, 2012
	Gross Carrying Amount		Accumulated Amortization			Net		Gross Carrying Amount		Accumulated Amortization			Net
Customer relationships	$	1,316.4	$	(529.7	)	$	786.7	$	1,296.1	$	(483.3	)	$	812.8
Patents, licenses and technology	117.2		(83.8		)	33.4		117.2		(76.2		)	41.0
Non-compete agreements	39.0		(23.9		)	15.1		32.3		(19.6		)	12.7
Trade names	131.3		(80.6		)	50.7		131.3		(73.4		)	57.9
Canadian licenses	715.5		—			715.5		743.3		—			743.3
	$	2,319.4	$	(718.0	)	$	1,601.4	$	2,320.2	$	(652.5	)	$	1,667.7

Amortization of intangible assets for the three and nine months ended September 30, 2013 was $20.3 and $60.3, respectively; and $21.1 and $63.1 for the three and nine months ended September 30, 2012, respectively. Amortization expense for the net carrying amount of intangible assets is estimated to be $25.2 for the remainder of fiscal 2013, $82.7 in fiscal 2014, $79.1 in fiscal 2015, $73.8 in fiscal 2016, $66.7 in fiscal 2017 and $544.0 thereafter.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details